Grace Therapeutics, Stock Today
| GRCE Stock | 2.55 0.22 9.44% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Grace Therapeutics, is trading at 2.55 as of the 20th of March 2025, a 9.44% up since the beginning of the trading day. The stock's lowest day price was 2.42. Grace Therapeutics, has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Grace Therapeutics, symbol was changed from ACST on 28th of October 2024. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Moving together with Grace Stock
Moving against Grace Stock
Grace Stock Highlights
| Older Symbol | ACST |
| CEO Director | Prashant Kohli |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Biotechnology, Healthcare (View all Sectors) |
Grace Therapeutics, (GRCE) is traded on NASDAQ Exchange in USA. It is located in 103 Carnegie Center, Princeton, NJ, United States, 08540 and employs 4 people. Grace Therapeutics, was previously known as ACST Old and was traded on NASDAQ Exchange under the symbol ACST. Grace Therapeutics, is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 34.98 M. Grace Therapeutics, conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 10.14 M outstanding shares of which 375.57 K shares are currently shorted by private and institutional investors with about 0.42 trading days to cover.
Grace Therapeutics, generates negative cash flow from operations
Check Grace Therapeutics, Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Grace Therapeutics, is USD34.98 Million. Grace Therapeutics, secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Grace Ownership Details
Grace Therapeutics, Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Grace Therapeutics, market risk premium is the additional return an investor will receive from holding Grace Therapeutics, long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.1) | |||
| Jensen Alpha | (0.61) | |||
| Total Risk Alpha | (0.17) | |||
| Treynor Ratio | 0.9878 |
Grace Stock Against Markets
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Grace Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Grace Therapeutics,. If investors know Grace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Grace Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Grace Therapeutics, is measured differently than its book value, which is the value of Grace that is recorded on the company's balance sheet. Investors also form their own opinion of Grace Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Grace Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Grace Therapeutics,'s market value can be influenced by many factors that don't directly affect Grace Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Grace Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Grace Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.